<DOC>
	<DOCNO>NCT01896622</DOCNO>
	<brief_summary>Background : - People human immunodeficiency virus ( HIV ) often take several medication control disease . They may also need take medicine prevent blood clot . Taking kind medicine together cause bleeding problem . But might happen medication take different time . Researchers study two particular HIV drug ( ritonavir cobicistat ) interact blood clot medication . Objectives : -To understand HIV medicine blood clot medicine interact , doctor choose prescribe people take . Eligibility : - Healthy adult 18 70 year old medication . Design : - Participants screen physical exam medical history . Blood sample collect . Urine sample collect participant might become pregnant . - Participants visit National Institutes Health 7 time screen visit . Three visit last 12 hour . The 4 last 1 hour . - Participants take daily dose either study medication 22 day . They keep diary medicine take side effect . - Treatment monitor blood test 2 month . - When study one drug complete , next drug study begin different group participant .</brief_summary>
	<brief_title>The Interaction Two HIV Medications With Blood Clot Medications Healthy Volunteers</brief_title>
	<detailed_description>Advances antiretroviral ( ARV ) pharmacotherapy translate increased longevity improve quality life people live HIV ; hence , elderly individual comprise increase proportion today HIV population . Moreover , HIV infection become recognize condition characterize hypercoaguable state premature immunologic age . Potential interaction ARVs anticoagulant medication particular concern consider many elderly , even non-elderly HIV patient require short-term chronic anticoagulation prevent and/or treat systemic embolism . Dabigatran , administer dabigatran etexilate , oral irreversible , competitive direct thrombin inhibitor , show superior warfarin , non-inferior enoxaparin , prevent thromboembolism patient atrial fibrillation undergo orthopedic surgery , respectively . While dabigatran substrate Permeability-glycoprotein ( P-gp ) , inactivepro-drug , dabigatran etexilate , substrate P-gp . Co-administration dabigatran etexilate P-gp modulators result significant change dabigatran exposure . The pharmacokinetic enhancer , ritonavir cobicistat , inhibitor P-gp , expect increase plasma concentration dabigatran ; however , neither agent study combination dabigatran etexilate , date . Hence , purpose study determine whether separate co-administration ritonavir cobicistat dabigatran etexilate increase systemic exposure dabigatran healthy volunteer , , whether adjust administration time medication circumvent interaction . In open-label study , 32 healthy volunteer assign 1 2 group . Group A consist 16 subject take 22 day ritonavir ; Group B consist 16 subject take 22 day cobicistat . All subject receive 3 separate single dos dabigatran etexilate . Pharmacokinetic ( PK ) pharmacodynamics ( PD ) sample dabigatran occur Days 0 1 , Day 19 1 20 , Day 26 1 27 . The PD effect dabigatran characterized via ecarin clotting time ( ECT ) measurement . Dabigatran PK/PD parameter determine use non-compartmental method WinNonlin professional computer program ( version 5.2 ; Pharsight Corporation , Mountain View , CA ) . The following PK/PD parameter compare group : area curve 0 24 hour ( AUC0-24 ) , maximum total dabigatran plasma concentration ( Cmax ) , area curve 0 infinity hour ( AUC0- ) , time maximum plasma concentration ( tmax ) , terminal half-life ( T ( Omega ) ) , apparent oral clearance ( CL/F ) , area effect curve 0 24 hour ( AUEC0-24 ) , maximum effect ratio baseline ( ERmax ) .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>INCLUSION CRITERIA : A subject consider eligible study follow criterion meet : 1 . Between age 18 70 year . 2 . Judged healthy base medical history , physical examination , vital sign , 12lead ECG , clinical laboratory test ( liver function test [ LFTs ] less equal 2 time upper limit normal [ ULN ] , serum creatinine [ sCr ] less equal ULN . 3 . Subject agree storage specimens future research . 4 . Negative serum urine pregnancy test female childbearing potential . 5 . For female subject , willing prevent pregnancy ( ) practice abstinence ( b ) use effective nonhormonal and/or barrier method birth control , study period . EXCLUSION CRITERIA : A subject ineligible study 1 , , follow criterion meet : 1 . History HIV exposure/infection , determine positive ELISA/ Western Blot . 2 . History presence following : gastrointestinal disease , uncontrolled require daily treatment medication ( pancreatitis , peptic ulcer disease , etc . ) hepatitis ( assessed patient interview ) hepatic impairment renal impairment ( chronic acute renal failure insufficiency ) respiratory disease , uncontrolled require daily treatment medication ( asthma , chronic obstructive pulmonary disease , etc . ) cardiovascular disease ( hypertension [ systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg ] , heart failure , arrhythmia , etc . ) metabolic disorder ( diabetes mellitus , etc . ) immunologic disorder hormonal disorder psychiatric illness , would interfere ability comply study procedure require daily treatment medication seizure disorder , exception childhood febrile seizures malignancy , P3 Pharmacoenhancers &amp; Pradaxa , Pgp Substrate 26 condition may interfere interpretation study result , best interest subject opinion Investigator . 3 . History presence following : bleeding/hematologic disorder ( hemophilia , etc . ) serious/major bleed event ( intracranial , gastrointestinal , assessed patient interview ) c. current increase risk bleeding ( indicated aPTT &gt; 1.5 time ULN ] , platelet , PLT , &lt; 150,000/mm3 , Hgb &lt; 11 g/dL ) d. female subject , menorrhagia 4 . Planned invasive surgical procedure within ( prior , follow ) 28 day study participation . 5 . Fasting total cholesterol &gt; 270 mg/dL fast triglyceride &gt; 270 mg/dL . 6 . Fasting glucose &gt; 125 mg/dL . 7 . Concomitant routine therapy prescription , overthecounter , herbal , holistic medication , include hormonal contraceptive route , investigational drug 30 day prior receipt study medication ( Day 0 ) . 1 . Concomitant therapy ( chronic intermittent ) prescription , overthecounter , herbal , holistic medication allow study duration 2 . Intermittent use acetaminophen loperamide allow take , accord manufacturer recommendation , within 30 day prior study participation 3 . Intermittent use acetaminophen , loperamide , and/or antiemetic ( approved Principal Investigator ) allow take accord manufacturer recommendation study . As Pgp substrates , loperamide certain antiemetic ( i.e . ondansetron ) , take day pharmacokinetic blood sample 4 . A daily multivitamin mineral allow study 5 . Receipt influenza vaccination allow prior , , and/or study 6 . Use topical medication significantly absorb systemically allow approve Principal Investigator 8 . Inability obtain venous access sample collection . 9 . Inability swallow whole capsule and/or tablet . 10 . Positive serum urine pregnancy test breastfeed female . 11 . The presence persistent diarrhea malabsorption could interferewith subject ability absorb drug . 12 . Drug alcohol use may impair safety adherence . 13 . Use nicotinecontaining tobacco product , include cigarette chew tobacco . 14 . History intolerance allergic reaction ( rash ; hive ; swell lip ; difficulty breathe ) DE , RTV , COBI . 15 . Organ transplant recipient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 17, 2017</verification_date>
	<keyword>Dabigatran Etexilate</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Cobicistat</keyword>
	<keyword>P-Glycoprotein</keyword>
</DOC>